Physician profile
Michael Wayne Mccoy
NPI 1962518191
$9,213.79
in general payments reported to CMS, 2019-2025
25 companies · $415 in 2025
The $415 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $458 · 2021: $1,231 · 2022: $1,826 · 2023: $3,645 · 2024: $904 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,537 · Long Term Medical Supply Or Device Loan: $2,394 · Travel and Lodging: $31.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,537.31 |
| Long Term Medical Supply Or Device Loan | $2,394.00 |
| Travel and Lodging | $31.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $2,712.26 | 2022-2023 | Hillrom - Eli280 Cardiograph |
| Ironshore Pharmaceuticals INC. | $1,448.39 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $1,156.16 | 2021-2025 | Dyanavel Xr, Quillivant |
| Corium, LLC | $1,088.52 | 2021-2025 | Azstarys, Azstarys |
| Neos Therapeutics, LP | $881.27 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Supernus Pharmaceuticals, INC. | $793.05 | 2021-2025 | Qelbree, Qelbree |
| Cranial Technologies, INC | $222.51 | 2019-2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $120.93 | 2025 | Jornay Pm |
| Genentech USA, INC. | $103.17 | 2019-2021 | |
| Glaxosmithkline, LLC. | $97.11 | 2019-2023 | Bexsero |
| Adlon Therapeutics L.P. | $81.96 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.81 | 2019-2020 | |
| Kaleo, INC. | $62.36 | 2021-2022 | |
| Vertical Pharmaceuticals, LLC | $60.16 | 2024 | Relexxii |
| Inspire Medical Systems, INC. | $58.53 | 2024-2025 | Inspire |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $47.47 | 2019-2022 | |
| Avion Pharmaceuticals | $40.58 | 2023-2024 | Methylphenidate Hydrochloride |
| Seqirus USA INC | $34.30 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Aytu Biopharma, INC. | $29.37 | 2020-2024 | Karbinal |
| Shire North American Group INC | $20.14 | 2019 | |
| Merck Sharp & Dohme LLC | $18.75 | 2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Phadia US INC. | $18.30 | 2025 | Immunocap |
| Alk-Abello, INC | $16.47 | 2021 | |
| Pfizer INC. | $15.37 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.85 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mccoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.